Abstract
Arthritogenic alphaviruses are arboviruses (arthropod-borne viruses) that are genetically and serologically related positive-strand RNA viruses and cause epidemics on a global scale. They are transmitted by mosquitoes and cause diseases in humans that are mainly characterized by fever and often debilitating, sometimes chronic polyarthralgia. At present, approved treatments or vaccines are not available for most arthritogenic alphaviruses, and recently licensed vaccines against chikungunya virus are awaiting implementation in endemic areas. Most arthritogenic alphaviruses are currently limited to specific geographic areas due to vector distributions and availability of amplifying hosts, but they pose a substantial risk of emergence in other regions. The exception is chikungunya virus, which has emerged repeatedly from Africa, established sustained and efficient transmission in urban areas (including in temperate climates) and has caused major epidemics across the world. In this Review, we highlight recent advances in our understanding of the transmission cycles of arthritogenic alphaviruses, their vectors, epidemiology, transmission dynamics, evolution, pathophysiology and immune responses. We also outline strategies and countermeasures to anticipate and mitigate the impact of arthritogenic alphaviruses on human health.
| Original language | English |
|---|---|
| Pages (from-to) | 585-601 |
| Number of pages | 17 |
| Journal | Nature Reviews Microbiology |
| Volume | 23 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 2025 |
Bibliographical note
Publisher Copyright:© Springer Nature Limited 2025.
Funding
W.M.d.S. is supported by a Wellcome Trust Digital Technology Development Award in Climate Sensitive Infectious Disease Modelling (226075/Z/22/Z). M. L. is supported by grants from Institut Pasteur, Institut National de la Santé et de la Recherche Médicale, French National Research Agency and the European Research Council. S.C.W. is supported by National Institutes of Health grants (R24AI12094, U01AI151801 and AI121452). The authors thank Jacqueline A. Tida for drafting the figures.
| Funders | Funder number |
|---|---|
| French Agence Nationale de la Recherche | |
| Institut national de la santé et de la recherche médicale | |
| Institut Pasteur, Paris | |
| H2020 European Research Council | |
| Wellcome Trust | 226075/Z/22/Z |
| National Institutes of Health (NIH) | AI121452, U01AI151801, R24AI12094 |
ASJC Scopus subject areas
- Microbiology
- General Immunology and Microbiology
- Infectious Diseases